InvestorsHub Logo
Followers 234
Posts 26887
Boards Moderated 0
Alias Born 01/12/2013

Re: None

Sunday, 06/09/2019 10:51:22 AM

Sunday, June 09, 2019 10:51:22 AM

Post# of 425251
High Importance: ***

All Amarin investors short/long, retail or institutional must listen to
last Jefferies presentation. The content of the presentation is very aggressive but IMO factual.

I realize its difficult to be motivated by JT’s speeches, he comes off in an odd tone. For the first time in 8 years my better half (very smart business woman) listened... JT just doesn't sound excited enough to be holding a winning lottery ticket, but the facts remain...R-I is the most significant cardiovascular development since the invention of statins. The trial has enough zeros in the P value you need a calculator to add them! (Almost). This is just as excited as JT gets and for me that a perfect quality to have in a CEO holding the most significant cardiovascular trial results EVER!!! That’s right, the R-I trial confidently shows a reduction in cardiovascular deaths something you can’t find in any other single well done placebo controlled randomized clinical trial.

You must listen, the content sends chills down my spine.

Here:
http://wsw.com/webcast/jeff118/register.aspx?conf=jeff118&page=amrn&url=http%3A//wsw.com/webcast/jeff118/amrn/index.aspx

Once the media understands the content, Vascepa goes viral.

And IMO long investors will be making import decisions soon regarding the direction of Amarin Corp. While I recently changed my opinion in Amarin GIA or M&A in US; I have no intentions on giving my shares away. Let’s see some bigger investment banks comment on Vascepa lifecycle value...next week Goldman Sacs...DON’T MISS IT!!!

BB


If you're not good at being yourself, then maybe that's being yourself!

Volume:
Day Range:
Bid:
Ask:
Last Trade Time:
Total Trades:
  • 1D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
Recent AMRN News